Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS (DEMONSTRATE)
This study is currently recruiting participants.
Verified February 2012 by CID - Carbostent & Implantable Devices
Sponsor:
CID - Carbostent & Implantable Devices
Information provided by (Responsible Party):
CID - Carbostent & Implantable Devices
ClinicalTrials.gov Identifier:
NCT01543373
First received: February 20, 2012
Last updated: February 27, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to demonstrate the non-inferiority of Cre8 (CID) Drug Eluting Stent, studied 3 months after implant, compared to Vision/Multilink8 Bare Metal Stent (Abbott) studied at 1 month, in terms of neointimal coverage, determined by Optical Coherence Tomography (OCT), as percentage of cross-sections with RUTTS (Ratio of Uncovered to Total Stent Struts Per Cross Section) score ≤ 0.3.
| Condition | Intervention | Phase |
|---|---|---|
|
Stable Angina Unstable Angina NSTEMI |
Device: Amphilimus Eluting Stent Device: Bare Metal Stent |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Randomized Comparison Between a DES and a BMS to Assess Neointimal Coverage by OCT Evaluation |
Resource links provided by NLM:
Further study details as provided by CID - Carbostent & Implantable Devices:
Primary Outcome Measures:
- Ratio of Uncovered to Total Stent Struts Per Cross Section (RUTTS) score of ≤ 0.3, determined by OCT [ Time Frame: within 3 months from index procedure ] [ Designated as safety issue: Yes ]1 month for the BMS arm; 3 months for the DES arm
Secondary Outcome Measures:
- Percentage of malapposed stent struts [ Time Frame: Immediately post index procedure, 1 month (BMS arm) / 3 months (DES arm) ] [ Designated as safety issue: Yes ]
- Percentage of malapposed and uncovered stent struts [ Time Frame: 1 month (BMS arm) / 3 months (DES arm) ] [ Designated as safety issue: Yes ]
- Neointimal growth and neointimal thickness [ Time Frame: 1 month (BMS arm) / 3 months (DES arm) ] [ Designated as safety issue: No ]
- Angiographic in-stent and in-segment endpoints [ Time Frame: immediately pre and post index procedure, 1 month (BMS arm) / 3 months (DES arm) ] [ Designated as safety issue: No ]reference vessel diameter; minimal lumen diameter; % diameter stenosis; binary restenosis; late lumen loss
- Clinical composite endpoints [ Time Frame: At 1, 3 and 12 months ] [ Designated as safety issue: Yes ]
- Cardiac death/Target vessel MI/Clinically indicated TLR
- All death/All MI/All TVR (including TLR)
- Stent Thrombosis [ Time Frame: during index procedure, immediately after index procedure, 1 month, 3 months, 12 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 40 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: CRE8 arm |
Device: Amphilimus Eluting Stent
Sirolimus formulated coronary eluting stent
|
| Active Comparator: Vision/Multilik8 arm |
Device: Bare Metal Stent
Bare metal coronary stent
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age > 18 years;
- Patients with symptoms of stable or unstable angina and/or presence of a positive functional test for ischemia;
- Patient is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG);
- Left ventricular ejection fraction > 30%;
- Patients presenting with at least two vessels disease requiring a staged procedure within 3 months, according to the operator judgement;
- Target de-novo lesion;
- Target lesion located in a target vessel with a diameter ranging from 2.5 to 3.75 mm;
- Target lesion diameter stenosis > 50% and < 100% by visual estimate, with a TIMI flow of >=1;
- Discrete lesion with a length ranging from 13 to 25 mm;
- The target lesion must be appropriately covered (margin of 2.5 mm on both sides of the stent) by one study stent (Cre8 or Vision/Multilink 8), according to the randomization arm;
- Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee of the respective clinical site.
Exclusion Criteria:
- Female with childbearing potential or lactating;
- Patient presenting with acute myocardial infarction with ST elevation;
- Known allergies to antiplatelets, anticoagulants, contrast media, sirolimus or cobalt chromium;
- Cerebrovascular accident within the past 6 months;
- Acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl);
- Thrombocytopenia (platelet count less than 100,000/mm³);
- Known bleeding or hypercoagulable disorder;
- Currently under immunosuppressant therapy;
- Co-morbidities that could interfere with completion of study procedures, or life expectancy less than 1 year;
- Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study;
- Patient underwent target vessel revascularization with a DES;
- Heavily calcified vessel and/or lesion which cannot be successfully predilated or imaged by OCT
- Target lesion is located or supplied by an arterial or venous bypass graft;
- Lesion located very distally, difficult to be imaged by OCT;
- Lesion located in angulated (>70°), sharp take-off vessel;
- Target lesion involving a bifurcation with a side branch ≥2.0 mm in diameter;
- Target lesion located in the left main stem;
- Ostial lesion location;
- Target lesion has TIMI 0 flow;
- Target vessel with angiographically visible thrombus or unsuitable for proper stent delivery and deployment.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01543373
Contacts
| Contact: Cristina Isaia | 0039-0161-1826291 | cristina.isaia@cidvascular.com |
Locations
| Italy | |
| Azienda Ospedaliero - Universitaria S.Anna | Recruiting |
| Ferrara, FE, Italy, 44121 | |
| Principal Investigator: Marco Valgimigli, MD, PhD | |
| Azienda Ospedaliera S. Giovanni - Addolorata | Recruiting |
| Roma, RM, Italy, 00184 | |
| Principal Investigator: Francesco Prati, MD | |
| Policlinico Universitario "Agostino Gemelli" | Recruiting |
| Roma, RM, Italy, 00168 | |
| Principal Investigator: Francesco Burzotta, MD, PhD | |
| Presidio Ospedaliero Umberto I - Azienda Ospedaliera "Ordine Mauriziano di Torino" | Not yet recruiting |
| Torino, TO, Italy, 10128 | |
| Principal Investigator: Mauro De Benedictis, MD | |
| ULSS n°3 - Ospedale Civile | Recruiting |
| Bassano del Grappa, VI, Italy, 36061 | |
| Principal Investigator: Angelo Ramondo, MD | |
| Netherlands | |
| University Medical Centre Utrecht | Not yet recruiting |
| Utrecht, Netherlands | |
| Principal Investigator: Pieter Stella, MD, PhD | |
Sponsors and Collaborators
CID - Carbostent & Implantable Devices
Investigators
| Principal Investigator: | Francesco Prati, MD | Ospedale S. Giovanni - Addolorata |
More Information
No publications provided
| Responsible Party: | CID - Carbostent & Implantable Devices |
| ClinicalTrials.gov Identifier: | NCT01543373 History of Changes |
| Other Study ID Numbers: | C21101 |
| Study First Received: | February 20, 2012 |
| Last Updated: | February 27, 2012 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by CID - Carbostent & Implantable Devices:
|
Coronary artery disease Optical Coherence Tomography Tissue coverage DES |
Additional relevant MeSH terms:
|
Angina Pectoris Angina, Unstable Myocardial Ischemia Heart Diseases Cardiovascular Diseases |
Vascular Diseases Chest Pain Pain Signs and Symptoms |
ClinicalTrials.gov processed this record on May 16, 2013